Heterologous Versus Homologous COVID‐19 Boosters: Immune Response Outcomes in Renal Transplant Recipients
Journal of Medical Virology · 2024
DOI: 10.1002/jmv.70030 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Journal of Medical Virology, 2024. Verfasst von Yesim Yildiz und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Infectious Diseases and Clinical Microbiology, Faculty of Medicine, Gazi University, Ankara, Turkey. Hauptthemen laut MEDLINE: Kidney Transplantation, COVID-19, Antibodies, Viral, Immunization, Secondary. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: This study was supported by Gazi Üniversitesi..
Abstract (Originalsprache)
We aimed to investigate the immune responses to homologous and heterologous COVID‐19 booster vaccinations in renal transplant recipients (RTRs) and to identify factors affecting these responses. In this prospective multicenter observational study, we measured the antibody kinetics of 90 RTRs using the chemiluminescent microparticle immunoassay method. The mean age of participants was 45.2 ± 11.4 years, with 35.6% being female. On the 42nd day after the first vaccine dose, the median antibody level was 16.7 (IQR 2.5−249.5) AU/mL, and the seropositivity rate was 60% ( n = 36). Mycophenolic acid (MFA) (OR: 0.087, 95% CI: 0.024−0.311) and ACE inhibitor use (OR: 0.203, 95% CI: 0.052−0.794) were identified as independent factors affecting seropositivity. Patients who received the Pfizer/BioNTech booster had significantly higher antibody levels compared to those who received the CoronaVac/Sinovac booster ( p = 0.021). Additionally, a significantly higher rate of COVID‐19 positivity was observed among patients who received the CoronaVac/Sinovac booster ( p = 0.031). Heterologous COVID‐19 booster vaccination is significantly more effective than homologous inactivated booster vaccination in enhancing immune responses and preventing new infections in RTRs. MFA and ACE inhibitor usage were independent factors affecting seropositivity. Additional COVID‐19 vaccine doses are needed in this patient group.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Infectious Diseases and Clinical Microbiology, Faculty of Medicine, Gazi University, Ankara, Turkey.
- Department of Nephrology, Gazi University Faculty of Medicine, Ankara, Turkey.
- Department of Medical Microbiology, Gazi University Faculty of Medicine, Ankara, Turkey.
- Department of Nephrology, Bilkent City Hospital, Ankara Yildirim Beyazit University, Ankara, Turkey.
- Institute of Materials Science and Nanotechnology, Neuroscience Interdisciplinary Program, UNAM-National Nanotechnology Research Center, Bilkent University, Ankara, Turkey.
- Department of Public Health, Gazi University Faculty of Medicine, Ankara, Turkey.
ORCID-Profile: Yesim Yildiz, Emre Yasar, Ozant Helvaci, Hasan Selcuk Ozger, Pinar Aysert Yildiz
Förderung
- This study was supported by Gazi Üniversitesi.
Zitieren
APA
Yildiz, Y., Yasar, E., Ozturk, E., Karakan, M. S., Helvaci, O., Ozger, H. S., Cemre Araz, Z., Yildiz, P. A., Dikmen, A. U., Caglar, K., Dizbay, M., Derici, U., & Guz, G. (2024). Heterologous Versus Homologous COVID‐19 Boosters: Immune Response Outcomes in Renal Transplant Recipients. Journal of Medical Virology. https://doi.org/10.1002/jmv.70030
Vancouver
Yildiz Y, Yasar E, Ozturk E, Karakan MS, Helvaci O, Ozger HS, et al. Heterologous Versus Homologous COVID‐19 Boosters: Immune Response Outcomes in Renal Transplant Recipients. Journal of Medical Virology. 2024. doi:10.1002/jmv.70030
BibTeX
@article{Yildiz2024,
author = {Yildiz, Yesim and Yasar, Emre and Ozturk, Erensu and Karakan, Mine Sebnem and Helvaci, Ozant and Ozger, Hasan Selcuk and Cemre Araz, Z and Yildiz, Pinar Aysert and Dikmen, Asiye Ugras and Caglar, Kayhan and Dizbay, Murat and Derici, Ulver and Guz, Galip},
title = {Heterologous Versus Homologous COVID‐19 Boosters: Immune Response Outcomes in Renal Transplant Recipients},
journal = {Journal of Medical Virology},
year = {2024},
doi = {10.1002/jmv.70030}
}
EUVIMED